Literature DB >> 1708329

Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Single and multiple dosing studies.

H Tanaka1, T Kaneko.   

Abstract

The pharmacokinetics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) were investigated in male Sprague-Dawley rats at a dose of 5 micrograms/kg. The serum concentrations of rhG-CSF were monitored using a specific sandwich enzyme immunoassay. In single-dose studies, the influence of routes of administration were evaluated. For iv administration, the serum concentration-time data showed the rapid disappearance of rhG-CSF from the systemic blood and a mean residence time (MRT) of 1.341 hr. For sc, im, and ip administration, lower peak serum levels were observed, but after 2 to 3 hr, rhG-CSF levels were higher than those for iv administration. The MRTs after sc, im, and ip injections were 3.918, 2.894, and 3.538 hr, respectively. The serum concentration profiles after extravascular injections showed that an im injection gave slightly faster absorption kinetics of rhG-CSF from the injection site into systemic blood than did sc and ip injections. In multiple-dose studies, rhG-CSF was injected into animals iv and sc at 5 micrograms/kg/day for 7 days. On the day 7 the serum concentration-time profiles after rhG-CSF administration were compared between single and multiple dosing. The AUC after iv multiple dosing decreased by 17.4%, although half-lives and the volume of distribution were not significantly different between single and multiple dosing groups. The AUC after sc multiple dosing decreased by 25.6%; however, the bioavailability and observed maximum serum concentration of rhG-CSF were not significantly different. These results showed that the clearance of rhG-CSF increased after multiple dosing, although the mechanism of increased clearance was not apparent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708329

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Effects of granulocyte colony-stimulating factor on bacterial translocation due to burn wound sepsis.

Authors:  O Yalçin; G Soybir; F Köksoy; H Köse; R Oztürk; B Cokneşeli
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

2.  Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis.

Authors:  Artur Bauhofer; Alexander Torossian; Wilfried Lorenz; Martin Middeke; Ulrike Plaul; Philipp Schütz; Benno Stinner; Markus Hattel; Ilhan Celik
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

3.  Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the rabbit.

Authors:  R W Niven; F D Lott; A Y Ip; J M Cribbs
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

4.  Anti-obesity effects of granulocyte-colony stimulating factor in Otsuka-Long-Evans-Tokushima fatty rats.

Authors:  Yonggu Lee; Yi-Sun Song; Cheng-Hu Fang; Byung-Im So; Jun-Young Park; Hyun-Woo Joo; In-Hwa Park; Guang-Yin Shen; Jeong-Hun Shin; Hyuck Kim; You-Heon Ahn; Kyung-Soo Kim
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

Review 5.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

6.  The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.

Authors:  A Di Leo; E Bajetta; F Nolè; L Biganzoli; L Ferrari; S Oriana; G Riboldi; S Bohm; G Spatti; F Raspagliesi
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

7.  Albumin Modifies Responses to Hematopoietic Stem Cell Mobilizing Agents in Mice.

Authors:  Eva Danner; Halvard Bonig; Eliza Wiercinska
Journal:  Cells       Date:  2019-12-18       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.